Status: Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
Participants needed: 1,203
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Janssen Research & Development, LLCUpdated: Aug 25, 2026Locations: 173
Eligibility criteria
Histologically confirmed adenocarcinoma of the prostate [+9]
Venous thromboembolic events within 1 month prior to the first dose of study tre... [+4]